Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
Financial Statements
- Click here to download Vertex Pharmaceuticals, Inc.'s Income Statement
- Click here to download Vertex Pharmaceuticals, Inc.'s Balance Sheet
- Click here to download Vertex Pharmaceuticals, Inc.'s Statement of Cash Flows
Key Info
- Industry: Biotechnology
- Sector: Health Technology
- CEO Name: Reshma Kewalramani
Key Statistics
- Stock Price: $281.89
- Dividend Yield: 0%
- Market Capitalization: $73,423,042,630
- Shares Outstanding: 260,467,000
- Number of Employees: 3,000
- Trailing 12-Month EPS: $8.03
- Trailing 12-Month DPS: $N/A
- Payout Ratio: N/A%
Important Dates
- Next Earnings Date: 2020-10-21
- Next Ex-Dividend Date: None
Price Trends
- Current Stock Price: $281.89
- 52-week high: $306.08
- 52-week low: $165.23
- 200-day moving average: $252.5
- 50-day moving average: $281.25
Performance
- 1-Month Price Return: 0.8%
- 3-Month Price Return: 1.8%
- 6-Month Price Return: 23.5%
- 1-Year Price Return: 57.7%
- 2-Year Price Return: 88.2%
- 5-Year Price Return: 121.2%
Visit the Passiv Stock Directory
Data provided by IEX Cloud
September 3rd, 2020